Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist

被引:2
作者
Badr, Nahla M. [1 ,2 ]
Zaakouk, Mohamed [1 ,3 ]
Zhang, Qi [4 ]
Kearns, Daniel [5 ]
Kong, Anthony [1 ,6 ]
Shaaban, Abeer M. [1 ,5 ,7 ]
机构
[1] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, England
[2] Menoufia Univ, Fac Med, Dept Pathol, Shibin Al Kawm, Egypt
[3] Cairo Univ, NCI, Canc Pathol Dept, Giza, Egypt
[4] Shuwen Biotech Co Ltd, Hangzhou, Zhejiang, Peoples R China
[5] Queen Elizabeth Hosp Birmingham, Birmingham, England
[6] Kings Coll London, London, England
[7] Univ Birmingham, Queen Elizabeth Hosp Birmingham, Dept Cellular Pathol, Canc & Genom Sci, Birmingham B15 2TT, England
关键词
breast cancer; HER2; HER2-low; Ki67; oestrogen receptor; progesterone receptor; TUMOR-INFILTRATING LYMPHOCYTES; DEATH-LIGAND; ARTIFICIAL-INTELLIGENCE; PD-L1; EXPRESSION; SP142;
D O I
10.1111/his.15193
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
BackgroundThere are limited data on the role of multigene tests and their correlation with immunohistochemistry (IHC), especially on core biopsy. MammaTyper is a quantitative conformite Europeeanne (CE) marked, National Institute for Health and Care excellence (NICE) approved, in in vitro diagnostic quantitative real-time polymerase chain reaction (RT-qPCR) test for assessment of mRNA expression of four biomarkers (ESR1, PGR, ERBB2, MKI67).MethodsWe evaluated the concordance of MammaTyper with oestrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 by IHC on 133 core needle biopsies of breast cancer. HER2 was positive if IHC 3+ or 2+ and fluorescence in situ hybridization (FISH)-amplified. Global and hotspot Ki67 expression was analysed using a cutoff of >= 20% assessed manually and by digital image analysis. Agreements were expressed as overall percent agreement (OPA), positive percent agreement (PPA), negative percent agreement (NPA), and Cohen's kappa.ResultsRT-qPCR results of ESR1 were highly concordant with IHC with OPA of 94.7% using 1% cutoff and 91.7% when the low ER-positive category was included. The PPA and NPA between RT-qPCR and IHC for PR was 91.5% and 88.0%, respectively, when using the 1% cutoff. For ERBB2/HER2, the OPA was 95% and the PPA was 84.6%. 40 of 72 HER2 IHC score 0 tumours were classified as ERBB2 low. Best concordance between MKI67 by MammaTyper and Ki67 IHC was achieved using hotspot digital image analysis (OPA: 87.2%, PPA: 90.6%, NPA: 80%).ConclusionRT-qPCR-based assessment of the mRNA expression of ESR1, PGR, ERBB2, and MKI67 showed high concordance with IHC, suggesting that the MammaTyper test on core needle biopsies represents a reliable, efficient, and reproducible alternative for breast cancer classification and refining HER2 low categorisation. Comparison of ER, PR, HER2 expression by immunohistocgemistry and MammaTyper (R) RT-qPCR image
引用
收藏
页码:437 / 450
页数:14
相关论文
共 30 条
  • [1] Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
    Allison, Kimberly H.
    Hammond, M. Elizabeth H.
    Dowsett, Mitchell
    McKernin, Shannon E.
    Carey, Lisa A.
    Fitzgibbons, Patrick L.
    Hayes, Daniel F.
    Lakhani, Sunil R.
    Chavez-MacGregor, Mariana
    Perlmutter, Jane
    Perou, Charles M.
    Regan, Meredith M.
    Rimm, David L.
    Symmans, W. Fraser
    Torlakovic, Emina E.
    Varella, Leticia
    Viale, Giuseppe
    Weisberg, Tracey F.
    McShane, Lisa M.
    Wolff, Antonio C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) : 1346 - +
  • [2] Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification
    Allott, Emma H.
    Geradts, Joseph
    Sun, Xuezheng
    Cohen, Stephanie M.
    Zirpoli, Gary R.
    Khoury, Thaer
    Bshara, Wiam
    Chen, Mengjie
    Sherman, Mark E.
    Palmer, Julie R.
    Ambrosone, Christine B.
    Olshan, Andrew F.
    Troester, Melissa A.
    [J]. BREAST CANCER RESEARCH, 2016, 18
  • [3] Badr NM, 2022, EUR J CANCER, V175, pS59
  • [4] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
    Burstein, H. J.
    Curigliano, G.
    Thurlimann, B.
    Weber, W. P.
    Poortmans, P.
    Regan, M. M.
    Senn, H. J.
    Winer, E. P.
    Gnant, M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (10) : 1216 - 1235
  • [5] Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
    Chen, Chih-Jung
    Chen, Ting-Hao
    Lei, Jason
    Liang, Ji-An
    Yang, Po-Sheng
    Huang, Chiun-Sheng
    Hsieh, Chia-Ming
    Tseng, Ling-Ming
    Liu, Liang-Chih
    Cheng, Skye Hung-Chen
    Shih, Kuan-Hui
    [J]. BIOSCIENCE REPORTS, 2022, 42 (01)
  • [6] Long-term survival and intra-tumor heterogeneity of progesterone receptor expression in estrogen receptor-positive/progesterone receptor-positive premenopausal women with breast cancer
    Danielsson, Oscar
    Dar, Huma
    Perez-Tenorio, Gizeh
    Nordenskjold, Anna
    Yau, Christina
    Benz, Christopher C.
    Esserman, Laura J.
    Nordenskjold, Bo
    Stal, Olle
    Fornander, Tommy
    Johansson, Annelie
    Lindstrom, Linda S.
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [7] Correlation Between HER2 Determined by Fluorescence In Situ Hybridization and Reverse Transcription-Polymerase Chain Reaction of the Oncotype DX Test
    Dvorak, Leah
    Dolan, Michelle
    Fink, James
    Varghese, Linda
    Henriksen, Jonathan
    Gulbahce, H. Evin
    [J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2013, 21 (03) : 196 - 199
  • [8] Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
    Ellis, Matthew J.
    Suman, Vera J.
    Hoog, Jeremy
    Goncalves, Rodrigo
    Sanati, Souzan
    Creighton, Chad J.
    DeSchryver, Katherine
    Crouch, Erika
    Brink, Amy
    Watson, Mark
    Luo, Jingqin
    Tao, Yu
    Barnes, Michael
    Dowsett, Mitchell
    Budd, G. Thomas
    Winer, Eric
    Silverman, Paula
    Esserman, Laura
    Carey, Lisa
    Ma, Cynthia X.
    Unzeitig, Gary
    Pluard, Timothy
    Whitworth, Pat
    Babiera, Gildy
    Guenther, J. Michael
    Dayao, Zoneddy
    Ota, David
    Leitch, Marilyn
    Olson, John A., Jr.
    Allred, D. Craig
    Hunt, Kelly
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (10) : 1061 - +
  • [9] Filipits M, 2018, ANN ONCOL, V29, P480
  • [10] Food and Drug Administration (FDA), 2023, FDA expands early breast cancer indication for abemaciclib with endocrine therapy